October 2026 pulmonology highlights include FDA accelerated approval of Voceryq for recurrent respiratory papillomatosis and CHEST 2026 data.
|Videos|February 16, 2016
Q&A With Hormoz Ashtyani From Hackensack University Medical Center: Learning to Improve Diagnosis and Treatment of COPD
Author(s)Adam Hochron
The knowledge about COPD has grown in recent years but even with that increased knowledge applying that to patient diagnose and treatment has proved difficult for the medical community.
Advertisement
The knowledge about COPD has grown in recent years but even with that increased knowledge applying that to patient diagnose and treatment has proved difficult for the medical community.
Hormoz Ashtyani, MD, from Hackensack University Medical Center, now known as HackensackUMC addressed some of the challenges pulmonologists are facing with this expanding patient population affected by not only a longer life expectancy but also long durations of smoking.
Advertisement
Related to this article
Five CHEST 2026 interviews cover nalbuphine ER for IPF cough, tozorakimab in COPD, depemokimab remission, AD109 in OSA, and robotic bronchoscopy.
Alvar AgustĂ, MD, previews key 2027 GOLD report changes, from initial COPD treatment and new biologic data to a GOLD Science Committee call to action.
Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.
CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.
At GOLD 2026, Alvar AgustĂ, MD, PhD, speaks on COPD underdiagnosis and misdiagnosis, barriers to spirometry in primary care, and managing pre-COPD.
In a 50-patient rhinovirus challenge study, a single nasal ETH47 dose cut peak viral load 40-fold, though the primary endpoint was not significant.
HCPLive previews GOLD 2026 in Philadelphia, November 5-6, with sessions on the 2027 GOLD Report, mucus plugging, and exacerbations, plus expert interviews.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
3
Nasal mRNA ETH47 Lowers Rhinovirus Load in Asthma Challenge Study
4
ELSPIRE: Elafibranor Achieves ALP Normalization in 85% With PBC
5